These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 35076285)

  • 21. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
    Prelaj A; Tay R; Ferrara R; Chaput N; Besse B; Califano R
    Eur J Cancer; 2019 Jan; 106():144-159. PubMed ID: 30528799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2019 Jan; 31(1):24-28. PubMed ID: 30418192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
    Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promising predictors of checkpoint inhibitor response in NSCLC.
    Alex F; Alfredo A
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):931-937. PubMed ID: 32870120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.
    Russano M; La Cava G; Cortellini A; Citarella F; Galletti A; Di Fazio GR; Santo V; Brunetti L; Vendittelli A; Fioroni I; Pantano F; Tonini G; Vincenzi B
    Curr Oncol; 2023 Feb; 30(2):2366-2387. PubMed ID: 36826142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in 
Non-small Cell Lung Cancer].
    Wang P; Tang C; Liang J
    Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):503-512. PubMed ID: 34187157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.
    Sun LY; Cen WJ; Tang WT; Long YK; Yang XH; Ji XM; Yang JJ; Zhang RJ; Wang F; Shao JY; Du ZM
    Cancer Med; 2021 Oct; 10(19):6610-6617. PubMed ID: 34469045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of immunotherapy for non-small cell lung cancer.
    Shirasawa M; Yoshida T; Ohe Y
    Jpn J Clin Oncol; 2024 Jan; 54(1):13-22. PubMed ID: 37823218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].
    Zhang T; Li B
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):188-195. PubMed ID: 33819969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.
    Calles A; Riess JW; Brahmer JR
    Am Soc Clin Oncol Educ Book; 2020 May; 40():372-384. PubMed ID: 32421452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
    Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
    Qu J; Jiang M; Wang L; Zhao D; Qin K; Wang Y; Tao J; Zhang X
    Biomed Pharmacother; 2020 Jul; 127():109996. PubMed ID: 32388240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
    Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
    Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.